People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology, Other Health Care, Other, Restaurants
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | — | Biotechnology | Series C | $183.2M | $2.8B | 2016 |
| Voyager Therapeutics, Inc. | — | Biotechnology | Series C | $119.0M | $215.1M | 2015 |
| Foundation Medicine, Inc. | — | Biotechnology | Series C | $115.5M | $2.3B | 2010 |
| NinePoint Medical, Inc. | — | Other Health Care | Series B | $70.4M | $679.4M | 2009 |
| Eleven Biotherapeutics, Inc. | — | Biotechnology | Series B | $43.3M | $39.5M | 2010 |
| AllStar Deals, Inc. | — | Other | Series A | $5.6M | $77.9M | 2013 |
| Maki Shop Store 1 LLC | — | Restaurants | Pre-Seed | $200K | $874K | 2014 |
| Maki Shop Store 3 LLC | — | Restaurants | Pre-Seed | $200K | $874K | 2016 |
| KarsAmerica Finance LLC | — | Other | Pre-Seed | $170K | $3.9M | 2010 |
Mark Levin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Levin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.